25I-NBMD

25I-NBMD is a psychedelic and hallucinogenic drug that is part of the 2C family. It was first synthesized and documented in 2011 by Thomas McLean and David E. Nichols at Purdue University. They described it as a potent partial agonist for the 5-HT2A receptor.

History[edit | edit source]

The first synthesis of 25I-NBMD was reported in 2011 by Thomas McLean and David E. Nichols at Purdue University. They were working on a project to develop serotonin 5-HT2A receptor partial agonists as potential therapeutic agents. The compound was later found to have psychedelic properties.

Pharmacology[edit | edit source]

25I-NBMD acts as a potent partial agonist for the 5-HT2A receptor. The exact nature of the drug's effects and its full range of potential uses are not well understood, as it has not been extensively studied in humans.

Effects[edit | edit source]

The effects of 25I-NBMD are similar to those of other hallucinogenic drugs. Users report intense visual hallucinations, altered thinking processes, and a sense of euphoria. However, the drug can also cause negative effects such as anxiety, paranoia, and potentially dangerous changes in heart rate and blood pressure.

Legal Status[edit | edit source]

The legal status of 25I-NBMD varies by country. In the United States, it is classified as a Schedule I drug under the Controlled Substances Act. In the United Kingdom, it is a Class A drug under the Misuse of Drugs Act 1971.

References[edit | edit source]

25I-NBMD Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.